Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Overview of attention for article published in The Lancet, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 118 news outlets
blogs: 4 blogs

twitter: 139 X users
facebook: 1 Facebook page

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 81 Mendeley

Summary News Blogs X Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Elsevier醫學資訊站, 05 Jul 2023

Fruquintinib延長轉移性大腸直腸癌病患的存活期發表在《刺胳針》(The Lancet) 的研究顯示，癌症標靶藥物Fruquintinib顯著改善了轉移性大腸直腸癌病患的整體存活期 (Overall Survival；OS) 與無惡化存活期 (P…